708 Correlation between age and histology type with peripheral neuropathy in epithelial ovarian cancer patient receiving platinum based chemotherapy

Introduction/Background Epithelial Ovarian cancer is the most lethal gynaecological malignancy and platinum-based chemotherapy is the standard management for advanced epithelial ovarian cancer. However, high prevalence of platinum-induced peripheral neurotoxicity (PIPN) had been reported and there still few local data regarding neurotoxicity effect of platinum as well as the additional risk factor. We conduct this study to analyzed the prevalence, severity and risk factors of peripheral neuropathy among patients receiving platinum-based chemotherapy in advanced epithelial ovarian cancer. Methodology This is a cohort analytical study conducted at Universitas Andalas cancer Centre at Dr. M Djamil Central Hospital of Padang from January until December 2023. All of the patient diagnosed with advanced epithelial ovarian cancer stage IC3 – IVA which confirmed by histology examination and receive platinum chemotherapy. Demographic and clinical data was recorded and peripheral neuropathy was assessed with Toronto Clinical Neuropathy Scoring System before and two weeks after the patient completed chemotherapy Results There were 35 patients participated in the study, before chemotherapy most of patient had no neuropathy (71,4%) and 28,6% had mild neuropathy. After underwent chemotherapy, most of patient had neuropathy which mild and moderate neuropathy accounts for 40% and 25,7%, respectively. In older age (>40 years old) 80% patient had worsened neuropathy after chemotherapy. Meanwhile, in younger age, only 10% patient had worsened neuropathy. High grade serous carcinoma had more worsened neuropathy (84,6%). This study found significant association between chemotherapy (p=0,000) and age (p=0,000) with neuropathy but found no association with histological classification (p=0.065) Conclusion There is significant effect of platinum-based chemotherapy on neurotoxicity and the older age had higher risk to develop platinum-induce peripheral neurotoxicity Disclosures No Disclosure.